ClinicalTrials.gov record
Active, not recruiting Phase 3 Interventional

Study of ALXN2220 Versus Placebo in Adults With ATTR-CM

ClinicalTrials.gov ID: NCT06183931

Public ClinicalTrials.gov record NCT06183931. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 19, 2026, 9:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Amyloid Depleter ALXN2220 in Adult Participants With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Study identification

NCT ID
NCT06183931
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Enrollment
1,181 participants

Conditions and interventions

Interventions

  • ALXN2220 Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 90 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 10, 2024
Primary completion
Jun 6, 2027
Completion
Oct 4, 2027
Last update posted
Feb 22, 2026

2024 – 2027

United States locations

U.S. sites
36
U.S. states
21
U.S. cities
33
Facility City State ZIP Site status
Research Site Irvine California 92614
Research Site La Jolla California 92037
Research Site Palo Alto California 94304
Research Site San Francisco California 94143
Research Site Aurora Colorado 80045
Research Site Washington D.C. District of Columbia 20010
Research Site Jacksonville Florida 32224
Research Site Weston Florida 33331
Research Site Atlanta Georgia 30309
Research Site Atlanta Georgia 30322
Research Site Chicago Illinois 60611
Research Site Indianapolis Indiana 46202
Research Site Boston Massachusetts 02115
Research Site Boston Massachusetts 02118
Research Site Kansas City Missouri 64111
Research Site St Louis Missouri 63110
Research Site New York New York 10016
Research Site New York New York 10032
Research Site Stony Brook New York 11794
Research Site Chapel Hill North Carolina 27599
Research Site Durham North Carolina 27705
Research Site Cleveland Ohio 44195
Research Site Columbus Ohio 43210
Research Site Portland Oregon 97239
Research Site Danville Pennsylvania 17822
Research Site Philadelphia Pennsylvania 19104
Research Site Charleston South Carolina 29425
Research Site Greenville South Carolina 29605
Research Site Memphis Tennessee 38120
Research Site Fort Worth Texas 76104
Research Site Houston Texas 77030
Research Site Salt Lake City Utah 84132
Research Site Falls Church Virginia 22042
Research Site Richmond Virginia 23298
Research Site Seattle Washington 98195
Research Site Madison Wisconsin 53705

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 176 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06183931, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 22, 2026 · Synced May 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06183931 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →